Proteocyte AI

Home
Canada
Toronto, ON
Proteocyte AI

A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

04/07/2026

April is Oral Cancer Awareness Month.

Each year, more than 50,000 people in North America are diagnosed with oral cancer, yet survival rates have remained largely unchanged for decades.

Early detection and accurate risk prediction are critical to improving outcomes.

That’s where STRATICYTE® can make a difference.

Using AI-driven biomarker analysis and digital pathology, STRATICYTE® supplements traditional histopathology by providing an objective, personalized 5-year oral cancer risk score.

Better risk insight helps clinicians identify high-risk patients earlier and guide more personalized care.

Learn more about STRATICYTE®:
https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

03/27/2026

Advancing the science behind oral cancer risk prediction requires strong clinical evidence.

Proteocyte AI is encouraged by new clinical research that strengthens how clinicians assess the malignant transformation risk of oral potentially malignant disorders (OPMDs) including evidence supporting the STRATICYTE® test.

A recent multi-center retrospective study, a biomarker signature–based risk score (BRS) was shown to help identify which oral epithelial dysplasia (OED) lesions are more likely to progress to oral squamous cell carcinoma (OSCC) within five years.

Built on this scientific foundation the STRATICYTE® test combines proteomic biomarker analysis with digital pathology to deliver an objective, personalized 5-year oral cancer risk score. By extending beyond traditional histopathology alone, STRATICYTE® provides clearer insight to support more informed patient management.

A growing body of research continues to validate the role of biomarker-guided diagnostics in improving risk stratification for dysplastic oral lesions.

Dr. Simon Young, DDS, MD, PhD, FACS, Professor, Acting Department Chair, and Director of Research, UT Health Houston, and an author of the study, states, “This study highlights the potential role of molecular risk stratification in the management of oral dysplasia. A key strength of the assay in this cohort was its ability to identify patients at low risk of progression, which may help inform surveillance strategies, while higher scores may help flag patients who warrant closer follow-up. Further prospective validation will be important to define how best to integrate this tool into clinical decision-making.”

Explore Proteocyte AI’s clinical evidence and supporting research:
👉 https://proteocyte.com/publications/

Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

03/26/2026

April is Oral Cancer Awareness Month.

Each year, tens of thousands of people are diagnosed with oral cancer—yet 5-year survival rates have remained largely unchanged for decades. Early detection and accurate risk assessment remain critical challenges.

That’s why STRATICYTE® was developed.
Using AI-driven biomarker analysis and digital pathology, STRATICYTE® provides an objective, personalized 5-year oral cancer risk score, supplementing traditional histopathology to support earlier, more informed clinical decisions.

Accurate risk insight helps ensure timely intervention for high-risk patients, while reducing unnecessary treatment and anxiety for those at lower risk.

This Oral Cancer Awareness Month, we’re committed to advancing how risk is identified—so outcomes can finally change.

Learn more about STRATICYTE® and Proteocyte AI’s mission:
👉 https://proteocyte.com

Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

03/24/2026

Proteocyte AI is proud to be a Platinum Sponsor of the 2026 AAOM Annual Conference, taking place mid-April.

📍 Hyatt Regency DFW, 2334 N. International Pkwy, DFW Airport, TX 75261, USA
🗓️ April 22, 2026 - April 25, 2026

Accepted poster:
Identifying Malignant Transformation Risk of Dysplastic Oral Lesions with Straticyte®

We look forward to connecting with the oral medicine community and sharing how Straticyte® is advancing personalized oral cancer risk assessment.

Learn more about the conference: https://site.pheedloop.com/event/2026AAOM/home

Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

03/17/2026

You order the test. We do the rest.

STRATICYTE® is designed to integrate seamlessly into clinical workflows—providing objective, AI-powered risk stratification without adding complexity or burden.

By combining validated proteomic biomarker analysis with advanced digital pathology, STRATICYTE® goes beyond traditional histopathology to deliver a personalized 5-year oral cancer risk assessment.

Your STRATICYTE® report delivers clear, actionable insight—helping identify patients who may benefit from closer surveillance or earlier intervention, while avoiding overtreatment for those at lower risk.

Smarter risk assessment. Clearer decisions. Better patient management.

Learn how STRATICYTE® fits into your practice:
👉 https://proteocyte.com/straticyte/

Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events

03/12/2026

Oral cancer outcomes haven’t improved enough—and early insight matters.

Ask your healthcare provider about Straticyte®.
This clinically accredited test helps assess a patient’s personalized 5-year risk of oral cancer, supporting earlier, more informed care decisions.

Knowledge empowers conversations. Conversations can change outcomes.

Learn more at www.proteocyte.com

American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

03/10/2026

“Straticyte is an innovative new test that can help us to better risk stratify patients and personalize their treatment.”
— Dr. Deepak Kademani
Fellowship Director, Head and Neck Oncologic and Reconstructive Surgery
Minnesota Oral and Facial Surgery

STRATICYTE® can make a critical difference.
Using AI-driven biomarker analysis and digital pathology, STRATICYTE® supplements traditional histopathology by providing an objective, personalized 5-year oral cancer risk score.

Each STRATICYTE® report clearly classifies lesions as low risk or elevated risk, helping clinicians make more confident, evidence-based decisions around monitoring, intervention, and treatment planning.

Earlier insight enables smarter care—supporting timely intervention for high-risk patients while reducing unnecessary procedures for those at lower risk.

Learn more about STRATICYTE® and how it’s changing oral cancer risk assessment:
👉 https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

03/09/2026

Proteocyte AI would like to thank Dr. Jonathon Jundt (DDS, MD, FACS) and Allied OMS for the opportunity to speak with your membership about risk stratification in oral precancer—supporting our mission to bring early oral cancer prediction into everyday clinical practice.

Our team was proud to present “AI and Biomarker-Guided Diagnostics in Oral Lesions: Risk Stratification to Clinical Pathways,” alongside Dr. Anthony Morlandt and Dr. Paras B. Patel, whose passion and leadership continue to drive progress in oral disease diagnosis and surgical care.

Conversations like these are essential as the oral health community works toward earlier identification of high-risk lesions and more personalized patient management.

🎥 Watch the full presentation here:
https://vimeo.com/1166776243/70fe5d4b60

Learn more about STRATICYTE®, Proteocyte AI’s test designed to assess oral cancer risk:
https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

03/05/2026

Team Spotlight: Dr. Anthony Morlandt, MD, DDS, FACS

We’re proud to highlight Dr. Anthony Morlandt, Chief of Oral Oncology within the Department of Oral and Maxillofacial Surgery at the University of Alabama at Birmingham (UAB) Medicine. Dr. Morlandt is an academic head and neck surgeon with a focus on advancing oral cancer care. His oncology practice focuses on surgical treatment of tumors involving the oral cavity and oropharynx, salivary glands, skin of the head and neck, and skull base. His clinical and academic focus centers on helping clinicians and patients better understand individual risk associated with oral precancerous lesions.

His current research focuses on the use of prognostic biomarkers in the progression of oral dysplasia to cancer. His work has been published in more than 50 scientific articles and book chapters and he has given over 100 invited oral and video presentations. Dr. Morlandt received the Faculty Educator Development Award of the American Association of Oral and Maxillofacial Surgeons, the first in Alabama to do so. He has been inducted into the American Head and Neck Society and is a Fellow of both the American College of Surgeons and the American Association of Craniomaxillofacial Surgeons.
As Proteocyte AI's Chief Medical Officer, USA Dr. Morlandt’s expertise plays an important role in advancing the science behind STRATICYTE®, supporting more precise, patient-centered decision-making in oral cancer risk assessment.

“The Straticyte test represents an important step toward precision medicine in oral oncology, allowing clinicians to better risk-stratify dysplastic lesions and focus intervention on patients most likely to progress to cancer. By integrating objective molecular data with clinical judgment, we can move beyond qualitative histology alone and improve how we surveil and treat patients with potentially malignant oral disorders.”

🔗 Learn more: https://proteocyte.com/team/

Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

02/24/2026

At Proteocyte AI, quality is embedded in everything we do.

From training and technology development to clinical procedures and services, our work is guided by a robust Quality Management System (QMS) and stringent regulatory standards.

Our commitment ensures reliable results, clinical confidence, and continued innovation—because our patients and partners deserve nothing less than our best.

American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

02/17/2026

Ordering STRATICYTE® is simple, secure, and fully supported by Proteocyte AI Client Services.

👉 Complete Test Request Form: https://proteocyte.com/ordering-options/
📄 Submit order: 📧 Email: clientservices@proteocyte.com or 📠 Fax: 1-855-566-0488
📞 Questions? 📧 clientservices@proteocyte.com or 📱 1-833-577-6836

✔️ Secures payment from clinic or patient
✔️ Obtains unstained slides from the original OPMD biopsy lab
✔️ Facilitates specimen transfer to our lab*
✔️ Delivers the STRATICYTE® report in ~2–3 weeks from specimen receipt*

*Proprietary AI biomarker analysis and H&E and digitized image analysis performed at Proteocyte AI labs

US Lab Director: Dr. Paras Patel | CA Lab Director: Dr. Ken Pritzker

Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

02/10/2026

📄 New Research Supporting Predictive Biomarkers in OPMDs

A peer-reviewed study highlights S100A7 as a promising predictive biomarker for identifying oral potentially malignant disorders (OPMDs) at increased risk of transforming into oral squamous cell carcinoma (OSCC).

The study demonstrates that S100A7 expression—evaluated through immunohistochemistry and a signature risk algorithm—can differentiate transforming from non-transforming lesions with statistical significance.

This research reinforces the role of biomarker-driven, objective risk assessment in advancing oral cancer prediction and patient care.

🔗 Explore our publications: https://proteocyte.com/publications/

Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

Address

Toronto, ON
M5G1L7

Website

https://proteocyte.com/

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Proteocyte AI:

Shortcuts

Featured

Pablo Munoz
3080 Yonge Street Suite 5034
Rockyshores Counselling